Huntington National Bank Reduces Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Huntington National Bank cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 28.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,386 shares of the medical equipment provider’s stock after selling 560 shares during the period. Huntington National Bank’s holdings in Lantheus were worth $124,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LNTH. Geode Capital Management LLC boosted its stake in Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after buying an additional 32,551 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after acquiring an additional 3,772 shares in the last quarter. Empirical Asset Management LLC purchased a new stake in shares of Lantheus in the 4th quarter worth $323,000. Focus Financial Network Inc. bought a new stake in shares of Lantheus in the fourth quarter valued at about $292,000. Finally, Harbor Capital Advisors Inc. boosted its stake in shares of Lantheus by 12.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider’s stock valued at $13,006,000 after purchasing an additional 16,466 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Trading Down 6.5 %

NASDAQ LNTH opened at $90.92 on Monday. Lantheus Holdings, Inc. has a 12-month low of $58.46 and a 12-month high of $126.89. The company has a fifty day simple moving average of $93.31 and a two-hundred day simple moving average of $96.03. The stock has a market cap of $6.23 billion, a P/E ratio of 15.13 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Activity at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock worth $6,110,806 over the last quarter. Insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. B. Riley reduced their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Finally, Truist Financial raised their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.